KR
Karl Rothweiler
Investor at Inthera Bioscience AG
De Bilt, Utrecht
Overview
Karl Rothweiler is the Managing Partner at Aglaia Oncology Funds, an early-stage venture capital firm specializing in building next-generation life science companies. With a background in corporate law and finance, he has founded and invested in numerous successful startups in the pharmaceutical and biotech sectors, playing key roles in companies like Inthera Bioscience AG and Sapreme Technologies BV.
Rothweiler's career highlights include founding and investing in a range of innovative companies, such as Merus N.V. and InteRNA Technologies BV, and taking an active role in building companies from scratch, demonstrating his expertise in business development and strategy within the life science industry.
Work Experience
Managing Partner
2004 - Current
Founding Investor, Member of the Supervisory Board
2022
Founder, Founding Investor, Member of the Supervisory Board
2016
Member of the Remuneration Committee (Board)
Founding Investor, Member of the Supervisory Board
2015
Member of the Audit Committee (Board)
Founding Investor
2005
Sole investor during the 4-year start-up phase of this great Unicorn.
Founder, Founding Investor, Member of the Supervisory Board
2006 - 2023
Member of the Audit Committee (Board)
Founder, Founding Investor, Member of the Supervisory Board
2004 - 2017
Member of the Board following the incubation of and founding investments in the company.
Founder, Founding Investor
2005 - 2013
Founding Investor, Member of the Supervisory Board
2005 - 2011
Pivital role in the sale of the company to Byondis.
Founder
1995 - 2004
Early stage venturing in the internet space